Intelligent Ultrasnd - AGM Statement
22/06/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220622:nRSV6895Pa&default-theme=true
RNS Number : 6895P Intelligent Ultrasound Group PLC 22 June 2022
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Group" or the "Company")
AGM statement
Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic'
ultrasound company, specialising in artificial intelligence (AI) software and
simulation, announces that at the AGM due to be held today at 11:00am at the
offices of Memery Crystal, 165 Fleet Street, London EC4A 2DY, Non-Executive
Chairman Riccardo Pigliucci will make the following statement:
"As noted at the publication of our full year results, we have had a strong
start to 2022 and we continue to be confident in the upgraded market
expectations for the full year 2022 revenue. We remain excited about the
potential of our 'Classroom to Clinic' business."
The full voting results will be available on the website later today.
For further information, please contact:
Intelligent Ultrasound Group plc www. intelligentultrasound.com (http://intelligentultrasound.com/)
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Helen Jones, CFO
Cenkos Securities - Nominated Advisor and Broker
Giles Balleny/Max Gould (Corporate Finance) Tel: +44 (0)20 7397 8900
Michael Johnson/Julian Morse (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
(mailto:intelligentultrasound@walbrookpr.com)
Anna Dunphy/Paul McManus Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through simulation.
Our main products are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency Medicine training simulator
with Covid-19 module and the new BabyWorks Neonate and Paediatric training
simulator. To date over 1,350 simulators have been sold to over 650 medical
institutions around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines smarter and more
accessible using our proprietary ScanNav ultrasound image analysis technology.
Current products on the market utilising this technology are GE
Healthcare's SonoLyst software that is incorporated in their Voluson SWIFT
ultrasound machine; ScanNav Anatomy PNB that simplifies ultrasound-guided
needling by providing the user with real-time AI-based anatomy highlighting
for a range of medical procedures; and NeedleTrainer that teaches real-time
ultrasound-guided needling and incorporates ScanNav Anatomy PNB.
www.intelligentultrasound.com (http://www.intelligentultrasound.com/)
NOTE: ScanNav Anatomy PNB is CE approved, but not yet available for sale in
the US or any other territory requiring government approval for this type of
product.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END AGMSEUFIFEESEFM